Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 19 May 2015 | By Michael Mezher
The European Parliament is calling for new measures to combat antimicrobial resistance (AMR) in Europe, where 25,000 die each year due to drug-resistant infections.
Health authorities are increasingly citing AMR as one of the most pressing threats to global public health. In its 2014 Antimicrobial Resistance: global report on surveillance, the World Health Organization (WHO) called AMR "so serious that it threatens the achievements of modern medicine."
The rise of AMR is associated with the overuse and misuse of antimicrobial medicines such as antibiotics. When microbes targeted by a drug are not eliminated, treatment-resistant strains can be spread, which can have deadly consequences.
The problem is compounded by a significant decline in the development of new antimicrobial drugs in recent decades. The danger this can pose can be seen in the case of multidrug-resistant tuberculosis (MDR-TB), where over time strains of the bacteria have developed resistance to many previously effective treatments.
The proposal by the Members of European Parliament (MEPs) echoes previous calls for stricter control of the use of antibiotics in both human and veterinary populations.
For antibiotics used to treat humans, the MEPs propose to:
For animal populations, the MEPs point to new veterinary legislation currently under discussion, and urge companies to end prophylactic (preventative) antibiotic use and limit mass medication programs on farms.
Many of these measures reflect recent events, such as cases of carbapenem-resistant enterobacteriaceae (CRE) infections traced to insufficiently sterilized endoscopes and calls from the international community to delink the cost of antibiotics research and development from future sales. Stronger diagnostic requirements also have the potential to curb inappropriate antibiotic use in favor of more targeted treatment options that would reduce the need for retreatment.
In line with these measures, the MEPs are calling on the European Commission (EC) to adopt a new legislative framework to promote investment in new antibiotics. While the parliamentary proposal itself is not a legislative measure, it reflects increased awareness of the threat of AMR at a high level in EU politics.
European Parliament Press Release
Tags: Antimicrobial resistance, AMR, European Parliament
Regulatory Focus newsletters
All the biggest regulatory news and happenings.